Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20657045 | 0.87 | PTGS1 (0.55) | PTGS1SLC7A11ENPEP | |
| SCHEMBL1964879 | 0.87 | PTGS1 (0.55) | PTGS1SLC7A11ENPEP | |
| SCHEMBL8936197 | 0.86 | ANPEP (0.41) | PTGS1SLC7A11ENPEP | |
| Hydrochloric Acid SCHEMBL11053790 | 0.84 | PTGS1 (0.52) | PTGS1SLC7A11ENPEP | |
| Hydrochloric Acid SCHEMBL11053789 | 0.84 | PTGS1 (0.52) | PTGS1SLC7A11ENPEP | |
| SCHEMBL1373431 | 0.83 | PTGS1 (0.46) | PTGS1SLC7A11ENPEP | |
| SCHEMBL14775440 | 0.81 | PTGS1 (0.38) | PTGS1SLC7A11 | |
| SCHEMBL14645189 | 0.78 | ALOX15 (0.32) | — | |
| SCHEMBL2485960 | 0.78 | PTGS1 (0.46) | PTGS1SLC7A11ENPEP | |
| SCHEMBL11125227 | 0.78 | PTGS1 (0.50) | PTGS1SLC7A11ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12022829-B2 | Water-dispersible fine particle | TOYOBO CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| WO-2023083361-A1 | NEW METHOD FOR IMPROVING QUALITY OF PLATELETS | 上海循曜生物科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023069598-A1 | CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20220030861-A1 | WATER-DISPERSIBLE FINE PARTICLE | TOYOBO CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-3858136-A1 | WATER-DISPERSIBILE FINE PARTICLE | TOYOBO CO., LTD. (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3837281-A1 | PROTEIN FRAGMENTATION CONTROL STRATEGY BY RE-OXIDATION IN DOWNSTREAM CHROMATOGRAPHY | Bristol-Myers Squibb Company (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020241562-A1 | NANOPARTICLES AND METHOD FOR PRODUCING SAME | ユーハ味覚糖株式会社 | 2020-12-03 | — | — | WO | disclosed |
| WO-2020066912-A1 | WATER DISPERSIBILE FINE PARTICLE | 東洋紡株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020037016-A1 | PROTEIN FRAGMENTATION CONTROL STRATEGY BY RE-OXIDATION IN DOWNSTREAM CHROMATOGRAPHY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-20 | — | — | WO | disclosed |
| CN-109932503-B | Simulation experiment and noninvasive blood glucose detection method based on body heat production-heat dissipation model | 江苏精策医疗科技有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-7022672-B2 | Adding to the protein an aqueous solution of a charged polymer to reduce intermolecular or intramolecular interactions between positively and negatively charged domains | CHIRON CORPORATION (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1052963-A4 | COMPOSITIONS AND METHODS OF TREATING KERATIN-RELATED DISORDERS AND CONDITIONS | BUCK CAROL J (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20020137884-A1 | Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor | CHIRON CORPORATION | 2002-09-26 | — | — | US | disclosed |
| US-6348451-B1 | WOUND HEALING AGENTS FOR ANIMALS | PRO-NEURON, INC. | 2002-02-19 | — | — | US | disclosed |
| EP-1052963-A1 | COMPOSITIONS AND METHODS OF TREATING KERATIN-RELATED DISORDERS AND CONDITIONS | Buck, Carol J. (US) | 2000-11-22 | — | — | EP | disclosed |
| US-6117364-A | COMPRISING CINNAMALDEHYDE AND SPECIFIED ORGANOSULFUR COMPOUND(S); FREE OF ALKYLPHENOL ETHOXY COMPOUNDS; DOES NOT HAVE OIL FIELD ALDEHYDE/POLYACRYLAMIDE CROSSLINKING INCOMPATIBILITY; FOR ACID STIMULATION OF WELLS | NALCO/EXXON ENERGY CHEMICALS, L.P. (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1999040888-A1 | COMPOSITIONS AND METHODS OF TREATING KERATIN-RELATED DISORDERS AND CONDITIONS | BUCK CAROL J (US) | 1999-08-19 | — | — | WO | disclosed |
| EP-0608217-A1 | SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-08-03 | — | — | EP | disclosed |
| EP-0608217-A4 | SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION. | RES CORP TECHNOLOGIES INC (US) | 1993-12-06 | — | — | EP | disclosed |
| WO-1991016067-A1 | SOLUBLE AND STABLE SOURCES OF TYROSINE, CYSTEINE AND GLUTAMINE FOR TOTAL PARENTERAL NUTRITION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12022829-B2 | Water-dispersible fine particle | ABCG2, FIBP, MMP1 | PTGS1 1898/4885SLC7A11 591/4885ENPEP 3366/4885 |
| US-20220030861-A1 | WATER-DISPERSIBLE FINE PARTICLE | ABCG2, FIBP, MMP1 | PTGS1 1898/4885SLC7A11 591/4885ENPEP 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.